Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Treatment Room
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer · Source last updated 2024-01-02
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
Percentage of HCPs
Interval / dispersion
Not reported
Time frame
Day 1 of Cycle 6 (each cycle is 21 days)
What was measured
HCPs who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Patients will be moved outside of infusion unit to receive FDC SC; b) FDC SC route will allow more flexible scheduling; c) More patients will be treated in the infusion unit; d) Waiting list for any P+H IV treatment at the infusion unit will be reduced; e) Staff resources will be redistributed to other departments of the hospital; f) There will still be sufficient interaction time between HCPs and patients; g) Staff will spend more time for further education/development; h) Staff will dedicate more time attending to administrative tasks for Perjeta-Herceptin patients; i) Patients will spend less time in the care unit; j) Administration by FDC SC injection is preferred by patients."
Analysis population: The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6.
Groups in this outcome
All Healthcare Professionals
This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
A: P+H IV Followed by PH FDC SC
In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
B: PH FDC SC Followed by P+H IV
In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
All Healthcare Professionals
159
A: P+H IV Followed by PH FDC SC
79
B: PH FDC SC Followed by P+H IV
80
Reported measurements
Statement a): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
16.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
11.4
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
21.3
Not reported
Not reported
Not reported
Not reported
Statement a): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
15.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
12.7
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
17.5
Not reported
Not reported
Not reported
Not reported
Statement a): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
8.9
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
3.8
Not reported
Not reported
Not reported
Not reported
Statement a): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
21.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
26.6
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
16.3
Not reported
Not reported
Not reported
Not reported
Statement a): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
22.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
22.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
22.5
Not reported
Not reported
Not reported
Not reported
Statement a): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
12.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
13.9
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
11.3
Not reported
Not reported
Not reported
Not reported
Statement a): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement b): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
3.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
6.3
Not reported
Not reported
Not reported
Not reported
Statement b): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
8.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
7.6
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
10.0
Not reported
Not reported
Not reported
Not reported
Statement b): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
8.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
10.1
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement b): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
28.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
29.1
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
27.5
Not reported
Not reported
Not reported
Not reported
Statement b): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
45.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
49.4
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
41.3
Not reported
Not reported
Not reported
Not reported
Statement b): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement b): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement c): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
2.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
3.8
Not reported
Not reported
Not reported
Not reported
Statement c): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
7.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
7.6
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement c): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
15.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
17.7
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
12.5
Not reported
Not reported
Not reported
Not reported
Statement c): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
30.2
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
29.1
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
31.3
Not reported
Not reported
Not reported
Not reported
Statement c): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
37.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
36.7
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
37.5
Not reported
Not reported
Not reported
Not reported
Statement c): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement c): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement d): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
4.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement d): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
8.2
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
8.9
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement d): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
14.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
17.7
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
11.3
Not reported
Not reported
Not reported
Not reported
Statement d): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
27.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
29.1
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
26.3
Not reported
Not reported
Not reported
Not reported
Statement d): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
35.2
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
36.7
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
33.8
Not reported
Not reported
Not reported
Not reported
Statement d): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
3.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
2.5
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
5.0
Not reported
Not reported
Not reported
Not reported
Statement d): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
8.8
Not reported
Not reported
Not reported
Not reported
Statement e): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
12.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
15.2
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
10.0
Not reported
Not reported
Not reported
Not reported
Statement e): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
19.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
16.5
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
22.5
Not reported
Not reported
Not reported
Not reported
Statement e): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
20.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
17.7
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
22.5
Not reported
Not reported
Not reported
Not reported
Statement e): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
15.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
19.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
11.3
Not reported
Not reported
Not reported
Not reported
Statement e): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
19.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
20.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
18.8
Not reported
Not reported
Not reported
Not reported
Statement e): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
7.6
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
6.3
Not reported
Not reported
Not reported
Not reported
Statement e): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
8.8
Not reported
Not reported
Not reported
Not reported
Statement f): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
3.8
Not reported
Not reported
Not reported
Not reported
Statement f): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
6.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
3.8
Not reported
Not reported
Not reported
Not reported
Statement f): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
15.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
15.2
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
16.3
Not reported
Not reported
Not reported
Not reported
Statement f): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
32.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
31.6
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
32.5
Not reported
Not reported
Not reported
Not reported
Statement f): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
39.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
43.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
35.0
Not reported
Not reported
Not reported
Not reported
Statement f): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement f): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
8.8
Not reported
Not reported
Not reported
Not reported
Statement g): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
2.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
5.0
Not reported
Not reported
Not reported
Not reported
Statement g): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
9.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
7.6
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
11.3
Not reported
Not reported
Not reported
Not reported
Statement g): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
27.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
31.6
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
23.8
Not reported
Not reported
Not reported
Not reported
Statement g): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
21.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
20.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
22.5
Not reported
Not reported
Not reported
Not reported
Statement g): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
31.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
35.4
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
27.5
Not reported
Not reported
Not reported
Not reported
Statement g): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
2.5
Not reported
Not reported
Not reported
Not reported
Statement g): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement h): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
3.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
5.0
Not reported
Not reported
Not reported
Not reported
Statement h): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
13.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
11.4
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
16.3
Not reported
Not reported
Not reported
Not reported
Statement h): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
24.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
25.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
23.8
Not reported
Not reported
Not reported
Not reported
Statement h): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
20.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
24.1
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
16.3
Not reported
Not reported
Not reported
Not reported
Statement h): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
30.2
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
32.9
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
27.5
Not reported
Not reported
Not reported
Not reported
Statement h): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
2.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
3.8
Not reported
Not reported
Not reported
Not reported
Statement h): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.7
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement i): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement i): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
6.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
3.8
Not reported
Not reported
Not reported
Not reported
Statement i): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
3.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
5.0
Not reported
Not reported
Not reported
Not reported
Statement i): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
25.2
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
27.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
22.5
Not reported
Not reported
Not reported
Not reported
Statement i): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
60.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
60.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
60.0
Not reported
Not reported
Not reported
Not reported
Statement i): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement i): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
8.8
Not reported
Not reported
Not reported
Not reported
Statement j): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement j): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
8.9
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement j): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
12.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
10.1
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
15.0
Not reported
Not reported
Not reported
Not reported
Statement j): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
24.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
22.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
26.3
Not reported
Not reported
Not reported
Not reported
Statement j): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
50.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
53.2
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
47.5
Not reported
Not reported
Not reported
Not reported
Statement j): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement j): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
8.8
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
16.4
group Id
OG001
value
11.4
group Id
OG002
value
21.3
title
Statement a): Strongly Disagree
categories
measurements
group Id
OG000
value
15.1
group Id
OG001
value
12.7
group Id
OG002
value
17.5
title
Statement a): Disagree
categories
measurements
group Id
OG000
value
6.3
group Id
OG001
value
8.9
group Id
OG002
value
3.8
title
Statement a): Neutral
categories
measurements
group Id
OG000
value
21.4
group Id
OG001
value
26.6
group Id
OG002
value
16.3
title
Statement a): Agree
categories
measurements
group Id
OG000
value
22.6
group Id
OG001
value
22.8
group Id
OG002
value
22.5
title
Statement a): Strongly Agree
categories
measurements
group Id
OG000
value
12.6
group Id
OG001
value
13.9
group Id
OG002
value
11.3
title
Statement a): Not Applicable
categories
measurements
group Id
OG000
value
5.7
group Id
OG001
value
3.8
group Id
OG002
value
7.5
title
Statement a): Answer Missing
categories
measurements
group Id
OG000
value
3.1
group Id
OG001
value
0.0
group Id
OG002
value
6.3
title
Statement b): Strongly Disagree
categories
measurements
group Id
OG000
value
8.8
group Id
OG001
value
7.6
group Id
OG002
value
10.0
title
Statement b): Disagree
categories
measurements
group Id
OG000
value
8.8
group Id
OG001
value
10.1
group Id
OG002
value
7.5
title
Statement b): Neutral
categories
measurements
group Id
OG000
value
28.3
group Id
OG001
value
29.1
group Id
OG002
value
27.5
title
Statement b): Agree
categories
measurements
group Id
OG000
value
45.3
group Id
OG001
value
49.4
group Id
OG002
value
41.3
title
Statement b): Strongly Agree
denoms
counts
group Id
OG000
value
159
group Id
OG001
value
79
group Id
OG002
value
80
units
Participants
description
HCPs who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Patients will be moved outside of infusion unit to receive FDC SC; b) FDC SC route will allow more flexible scheduling; c) More patients will be treated in the infusion unit; d) Waiting list for any P+H IV treatment at the infusion unit will be reduced; e) Staff resources will be redistributed to other departments of the hospital; f) There will still be sufficient interaction time between HCPs and patients; g) Staff will spend more time for further education/development; h) Staff will dedicate more time attending to administrative tasks for Perjeta-Herceptin patients; i) Patients will spend less time in the care unit; j) Administration by FDC SC injection is preferred by patients."
groups
description
This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
id
OG000
title
All Healthcare Professionals
description
In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
id
OG001
title
A: P+H IV Followed by PH FDC SC
description
In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
id
OG002
title
B: PH FDC SC Followed by P+H IV
param Type
NUMBER
population Description
The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6.
reporting Status
POSTED
time Frame
Day 1 of Cycle 6 (each cycle is 21 days)
title
Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Treatment Room
Triangle